These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1038 related items for PubMed ID: 19030182

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire.
    Piault E, Evans CJ, Espindle D, Kopp Z, Brubaker L, Abrams P.
    Neurourol Urodyn; 2008; 27(3):179-90. PubMed ID: 17565727
    [Abstract] [Full Text] [Related]

  • 3. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.
    Chapple C, DuBeau C, Ebinger U, Rekeda L, Viegas A.
    Curr Med Res Opin; 2007 Oct; 23(10):2347-58. PubMed ID: 17706004
    [Abstract] [Full Text] [Related]

  • 4. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS, Elinoff V, Gordon DA, Deng DY, Brodsky M, Glasser DB, Jumadilova Z, Carlsson M.
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The psychometric validation of the OAB family impact measure (OAB-FIM).
    Coyne KS, Matza LS, Brewster-Jordan J, Thompson C, Bavendam T.
    Neurourol Urodyn; 2010 Mar; 29(3):359-69. PubMed ID: 19274760
    [Abstract] [Full Text] [Related]

  • 8. The responsiveness of the OAB-q among OAB patient subgroups.
    Coyne KS, Matza LS, Thompson C, Jumadilova Z, Bavendam T.
    Neurourol Urodyn; 2007 Mar; 26(2):196-203. PubMed ID: 17016794
    [Abstract] [Full Text] [Related]

  • 9. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M.
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [Abstract] [Full Text] [Related]

  • 13. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
    Chapple C, Steers W, Norton P, Millard R, Kralidis G, Glavind K, Abrams P.
    BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [Abstract] [Full Text] [Related]

  • 15. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.
    Haab F, Corcos J, Siami P, Glavind K, Dwyer P, Steel M, Kawakami F, Lheritier K, Steers WD.
    BJU Int; 2006 Nov; 98(5):1025-32. PubMed ID: 16879437
    [Abstract] [Full Text] [Related]

  • 16. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
    Foote J, Glavind K, Kralidis G, Wyndaele JJ.
    Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219
    [Abstract] [Full Text] [Related]

  • 17. Comprehensive evaluation of bladder and urethral dysfunction symptoms: development and psychometric validation of the Urinary Symptom Profile (USP) questionnaire.
    Haab F, Richard F, Amarenco G, Coloby P, Arnould B, Benmedjahed K, Guillemin I, Grise P.
    Urology; 2008 Apr; 71(4):646-56. PubMed ID: 18313122
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.
    Dwyer P, Kelleher C, Young J, Haab F, Lheritier K, Ariely R, Ebinger U.
    Neurourol Urodyn; 2008 Apr; 27(6):540-7. PubMed ID: 18663723
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.